García EA, Delgado MJC, Mukodsi CM, Campbell MM

Language: Spanish
References: 10
Page:
PDF size: 133.92 Kb.

ABSTRACT

In fibromyalgia, the oxidative stress is notable in his pathophysiology. The hyperbaric medicine produces hyperoxia, decreasing the reactive species of the oxygen. It made an investigation to evaluate the efficiency of the treatment with hyperbaric chamber in patients with Fibromyalgia, clinical trial pilot type, using clinical and epidemiological methods, of longitudinal cut, prospective time from January 2011 to July 2012. It included 20 patients treated with hyperbaric chamber in three cycles, of 10 sessions, every three months. It evaluated quality by means of the test Fibromyalgia Impact Questionnaire and looked for the apparition of adverse events.
The age bracket with greater prevalence of fibromyalgia was 40-49 years, favorable relationship to the feminine sex, predominate divorced civil state, university school level and with labor work. The 90 % had satisfactory answer to the treatment. It did not report toxicity.
We conclude the study backs to use hyperbaric chamber in the treatment of Fibromyalgia. Additional wider studies are required.

REFERENCES

1. Fibromyalgia: the Copenhagen declaration. Lancet. 1992; 340:663-4.

2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. ArthritisRheum. 1990; 33:160-72.

3. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int. [revista en Internet]. 2006; 26:598-603 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16283318&dopt=Abstract

4. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep. [revista en Internet]. 2006; 11:131-5 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16805968&dopt=Abstract

5. Sendur OF, Turan Y, Tastaban E, Yenisey C, Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int. [revista en Internet]. 2009; 29:629-33 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18853166&dopt=Abstract

6. Cordero MD, de Miguel M, Moreno-Fernández AM. Mitochondrial dysfunction in fibromyalgia and its implication in the pathogenesis of disease. Med Clin (Barc) [revista en Internet]. 2010 Apr 24 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=199336865dopt=Abstract

7. Menzies V, Lyon DE. Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs. [revista en Internet]. 2010; 11:387-94 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19933683&dopt=Abstract

8. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. [revista en Internet]. 2008; 32:179-83 [citado el 23 de abril de 2012]. Disponible en: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19096114&dopt=Abstract

9. Cohen H, Newman L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic disfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Sem Arthritis Rheum. 2000; 29: 217-27.

10. Albornoz J, Povedano J, Quijada J, De la Iglesia JL, Fernández A, Pérez-Vílchez D, et al. Características clínicas y sociolaborales de la fibromialgia en España: descripción de 193 pacientes. RevEspReumatol. 1997; 24:38-44.